Table 1.

Key 3rd line trials for metastatic gastric cancer.

Name of trial	ICI	Comp	N	OS (months)			PFS (months)			ORR (%)		References
				ICI	Comp	HR	ICI	Comp	HR	ICI	Comp
ATTRACTION-2	Nivo	Placebo	493	5.3	4.1	0.6	1.6	1.4	0.6	11	0	(35)
KEYNOTE-059	Pembro	NA	259	5.6	NA	NA	2.0	NA	NA	12	NA	(36)
JAVELIN 300	Avel	Pacli or Irino	371	4.6	5.0	1.1	1.4	2.7	1.7	2	4	(23)

ICI, immune checkpoint inhibitor; Comp, comparator arm; N, number of patients enrolled in the study; ORR, objective response rate; nivo, nivolumab; pembro, pembrolizumab; pacli, paclitaxel; avel, avelumab; irino, irinotecan.